BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18987526)

  • 1. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience.
    Gmeiner Stopar T; Fettich J; Zver S; Mlinaric-Rascan I; Hojker S; Socan A; Peitl PK; Mather S
    Nucl Med Commun; 2008 Dec; 29(12):1059-65. PubMed ID: 18987526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.
    Stopar TG; Mlinaric-Rascan I; Fettich J; Hojker S; Mather SJ
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):53-9. PubMed ID: 16172899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
    Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
    Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
    Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.
    Camacho X; Machado CL; García MF; Gambini JP; Banchero A; Fernández M; Oddone N; Bertolini Zanatta D; Rosal C; Buchpiguel CA; Chammas R; Riva E; Cabral P
    Oncology; 2017; 92(4):229-242. PubMed ID: 28196364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.
    Boucek JA; Turner JH
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
    Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
    Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
    Jazirehi AR; Gan XH; De Vos S; Emmanouilides C; Bonavida B
    Mol Cancer Ther; 2003 Nov; 2(11):1183-93. PubMed ID: 14617792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.
    Pandey U; Kameswaran M; Dev Sarma H; Samuel G
    Appl Radiat Isot; 2014 Apr; 86():52-6. PubMed ID: 24486518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
    Smith MR; Joshi I; Jin F; Obasaju C
    BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology.
    Dias CR; Jeger S; Osso JA; Müller C; De Pasquale C; Hohn A; Waibel R; Schibli R
    Nucl Med Biol; 2011 Jan; 38(1):19-28. PubMed ID: 21220126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
    Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
    Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma.
    Natarajan A; Hackel BJ; Gambhir SS
    Clin Cancer Res; 2013 Dec; 19(24):6820-9. PubMed ID: 24097872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma.
    Holmberg LA; Maloney D; Bensinger W
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):135-9. PubMed ID: 17026825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
    De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
    Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.